Category Archives: Topics

The EC Grants Tecartus Conditional Marketing Authorization for r/r MCL; UPDATED: US CAR-T Approvals Table

New content: The Celltelligence team has included and updated its CAR-T indications table for estimated approvals and submissions in the US (see below for download). 

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on Bayer’s and Atara’s Collaboration to Develop Solid Tumor CAR-T Therapies

On Sunday, December 6, Bayer and Atara Biotherapeutics announced (Bayer press release / Atara press release) a collaboration and worldwide license agreement. The collaboration covers research, development, and manufacturing milestones for mesothelin-targeting CAR-T therapies in high mesothelin-expressing solid tumors. Of note, the agreement includes the development of ATA2271 (an autologous mesothelin-targeting CAR-T) and its allogeneic version ATA3271 to treat malignant pleural mesothelioma and non-small-cell lung cancer. Below, Celltelligence provides thoughts on Bayer’s growing cell therapy portfolio, a possible strategy for advancing cell therapies, and if they will license Atara’s allogeneic CD19 CAR-T.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

What is Behind Ide-cel’s mPFS and mOS Disparity? Thoughts on Ide-cel’s Launch Messaging and List Price; bb21217’s Manufacturing Updates; bluebird bio ASH Investor Event

On Monday, December 7, bluebird bio held an ASH-related investor event (press release / webcast) discussing recent advances to their BCMA CAR-Ts ide-cel (bb2121) and bb21217 in r/r MM. Below, Celltelligence provides thoughts on the significant differences in ide-cel’s mPFS and mOS data, how the data could influence launch messaging and list price, in addition to summarizing manufacturing updates for bb21217.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Clinical Updates and Market Opportunities for AUTO1 and AUTO3; ASH Day 3 Autolus Investor Event

On Monday, December 7, 2020, Autolus held an investor event (presentation / webcast) discussing recent advances to their AUTO1 (CD19 CAR-T) in ALL and AUTO3 (CD19/CD22 CAR-T) in DLBCL programs. Below, Celltelligence provides insights into AUTO3’s potential use in the outpatient setting and AUTO1’s market opportunity in adult and pediatric ALL.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Could Cilta-cel Become the BCMA CAR-T of Choice in 2021? ASH Day 3 Legend Investor Event

On the third day of ASH 2020, Legend held an investor event to discuss the recent data presented at ASH 2020 from the Ph1b/2 CARTITUDE-1 study. Below, Celltelligence provides a summary of the call, JNJ’s / Legend’s possible messaging for cilta-cel, and regulatory updates in the US and EU.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

AUTO3 Outpatient Data in the Ph1/2 ALEXANDER Study; Updated Results for Liso-cel in the TRANSCEND CLL 004 Trial; ZUMA-5 Primary Analysis and Re-treatment; ASH Day 3

On the third day of ASH 2020, four key clinical updates were presented from Autolus, BMS and Gilead. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

ZUMA-12 Reports an 85% ORR in 1L DLBCL; Liso-cel’s Safety Profile vs Kymriah and Yescarta; Comparison of OOS Use of CD19 Commercial CAR-Ts; ASH Day 2

On the second day of ASH 2020, four key clinical updates were presented from Novartis, Gilead, and BMS / bluebird bio. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Kymriah Demonstrates a Favorable Safety Profile in FL; Updated Results for AUTO1’s Ph1 ALLCAR19 Trial in ALL and iNHL; Initial Data from Cellectis’s UCART22 Ph1 BALLI-01 Study; ASH Day 1 Encore

On the first day of ASH 2020, three key clinical updates were presented from Novartis, Autolus, and Cellectis. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Updated Results for ALLO-715 from ASH and Allogene’s Investor Call; CARsgen Fully Human BCMA CART CT053 Reports a 94% ORR in MM; Poseida Modifies Their P-BCMA-101 CAR-T Manufacturing Process; ASH Day 1 Encore

On the first day of ASH 2020, four key clinical updates were presented from Allogene, CARsgen and Poseida. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

CARTITUDE-1 Demonstrates Potential Best-in-Class Efficacy; Ide-cel’s CRB-401 Study Updates mDoR Data; Clinical and Manufacturing Updates for bb21217; A Comparison of Tecartus vs Liso-cel in MCL; Day 1 ASH 2020 Highlights

On the first day of ASH 2020, four key clinical updates were presented from BMS / bluebird, JNJ / Legend, and Gilead. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.